ARID1A and neoplasm: In the absence of pharmacological treatment, ARID1A knockdown markedly decreased tumor clone development; under SR-4835 treatment, ARID1A-deficient cells demonstrated improved sensitivity to CDK13 inhibitors (Fig. 4F-I; Additional file 4: Fig. S3A-C).